IRLAB Therapeutics has announced top-line results from the Phase IIb REACT-PD study evaluating its second most clinically advanced asset, pirepemat, as a potential treatment for falls related to Parkinson's disease (PF-Falls), a common comorbidity to the condition. The company has noted that, while ...Den vollständigen Artikel lesen ...
© 2025 Edison Investment Research